Ritholtz's Reads

Ritholtz's Reads: Drug Prices, Benchmarking and Trump

Here are your Wednesday morning reads.

My when is it going to stop raining in Portland? Turkish coffee reads:

  • Fund managers lose out from benchmarking (FT), see also The Pitfalls of Benchmarking (A Wealth of Common Sense)
  • A Cheaper Way to Battle Recession (Bloomberg View)
  • The Amazon Tax (Stratechery)
  • Why Don’t Investors Stay True to Their Principles? Think Self-Deception (ThinkAdvisor), see also Buy & Hold Can Be Risky, Too (Capital Spectator)
  • How Americans’ Perceptions of the Economy Have Changed in Just Three Months (Real Time Economics)
  • The Koch Brothers Have Started a New Family Office to Quietly Invest Their Fortune (Bloomberg)
  • Ouch! Name-brand prescription drug prices in the US have doubled in the last five years (Quartz)
  • DOJ’s Clear Threat to Go After Apple’s Source Code (emptywheel)
  • The macabre truth of gun control in the US is that toddlers kill more people than terrorists do (Guardian)
  • How to Steal a Nomination From Donald Trump (Bloomberg)

Feel the Burn

3_16

This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.

    To contact the author of this story:
    Barry Ritholtz at britholtz3@bloomberg.net

    To contact the editor responsible for this story:
    Zara Kessler at zkessler@bloomberg.net

    Before it's here, it's on the Bloomberg Terminal.
    LEARN MORE